From bench to bed: the current genome editing therapies for glaucoma

HIGHLIGHTS

  • who: Glaucoma and colleagues from the Eye Center of Xiangya Hospital, Central South University, Changsha, China, Hunan Key Laboratory of Ophthalmology have published the article: From Bench to Bed: The Current Genome Editing Therapies for Glaucoma, in the Journal: (JOURNAL)

SUMMARY

    Glaucoma is a group of optic neuropathies featured by degeneration of retinal ganglion cells (RGCs) and loss of their axons in the optic nerve (Jonas et_al, 2017). By 2020, there were an estimated 80 million glaucoma patients with approximately 11.2 million people being blind, making glaucoma a leading cause of irreversible . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?